Program
Meloxicam
Also written as “HTX-011”, “N1539” and “Meloxicam tablet”.
Its studies are mostly in Pain, Postoperative · Osteoarthritis · Arthritis, Rheumatoid · Hernia, Inguinal · Pain, led by 16 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 220 open or running | phase 4since Jul 4, 2014 | May 2, 2002 | none ahead |
| Heron Therapeutics | 161 open or running | phase 4since Oct 1, 2021 | Jun 9, 2015 | none ahead |
| Baudax Bio | 70 open or running | phase 4since Mar 15, 2022 | Aug 31, 2015 | none ahead |
| Alkermes | 30 open or running | phase 3since Sep 15, 2011 | Jul 23, 2009 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Jul 12, 2010 | Jul 12, 2010 | none ahead |
| Eurofarma Laboratorios | 20 open or running | phase 3since Apr 24, 2012 | Apr 24, 2012 | none ahead |
| Grünenthal | 20 open or running | phase 3since Sep 22, 2014 | Mar 18, 2013 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Feb 6, 2009 | Feb 6, 2009 | none ahead |
| Viatris | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| GlaxoSmithKline | 10 open or running | no phasesince Nov 28, 2012 | Nov 28, 2012 | none ahead |
| joint-stock-company-farmak | 10 open or running | phase 1since Nov 15, 2021 | Nov 15, 2021 | none ahead |
| Pfizer | 10 open or running | no phasesince Sep 6, 2011 | Sep 6, 2011 | none ahead |
| Sino Biopharmaceutical | 11 open or running | phase 2since Jul 10, 2023 | Jul 10, 2023 | none ahead |
| yangtze-river-pharmaceutical-group-co-ltd | 10 open or running | phase 3since Mar 25, 2025 | Mar 25, 2025 | none ahead |
| zodiac-produtos-farmaceuticos-s-a | 10 open or running | phase 3since May 11, 2015 | May 11, 2015 | none ahead |
Also a collaborator on its studies: eurotrials-brasil-consultores-cientificos-ltda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Jan 15, 2008.
- Sep 24, 2018Phase 1 study in HealthyBoehringer Ingelheim · NCT03684265 · 26 enrolled · Russian Federation
- Oct 1, 20182 phase 2 studies in Pain, PostoperativeHeron Therapeutics · NCT03695367, NCT03718039
- Apr 5, 2019Phase 3 study in AgnosiaHeron Therapeutics · NCT03907176 · 209 enrolled · United States
- Apr 17, 2019Phase 2 study in AgnosiaHeron Therapeutics · NCT03922048
- Apr 29, 2019Phase 3 study in Osteoarthritis, KneeEurofarma Laboratorios · NCT03936192
- May 9, 2019Phase 2 study in Pain, PostoperativeHeron Therapeutics · NCT03955211 · 25 enrolled · United States
- Jun 3, 2019Phase 3 study in AgnosiaHeron Therapeutics · NCT03974932 · 116 enrolled · United States
- May 27, 2021Phase 2 study in Pain, PostoperativeHeron Therapeutics · NCT04911062 · 32 enrolled · United States
- Oct 1, 2021Phase 4 study in AgnosiaHeron Therapeutics · NCT05109312 · 90 enrolled · United States
- Nov 15, 2021joint-stock-company-farmak's first study: phase 1 study in PharmacokineticsNew to joint-stock-company-farmakjoint-stock-company-farmak · NCT05125588 · 24 enrolled
- Mar 15, 2022Phase 4 study in Pain, PostoperativeBaudax Bio · NCT05315479 · 19 enrolled · United States
- Jul 10, 2023Sino Biopharmaceutical's first study: phase 2 study in Pain, PostoperativeNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05950152 · 108 planned · China
- Oct 25, 20232 phase 4 studies in Pain, PostoperativeHeron Therapeutics · NCT06109428, NCT06109415
- Mar 25, 2025yangtze-river-pharmaceutical-group-co-ltd's first study: phase 3 study in Participants With Acute Moderate to Severe Pain Following Abdominal SurgeryNew to yangtze-river-pharmaceutical-group-co-ltdyangtze-river-pharmaceutical-group-co-ltd · NCT06904248 · 224 enrolled · China
TargetBeta
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule
Other programs on PTGS2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| Celecoxibrule | Viatris | phase 4 | 78 |
| Etoricoxibrule | Organon | phase 4 | 35 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
The newest 60 of 66 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06904248Participants With Acute Moderate to Severe Pain Following Abdominal Surgery · China | 3 | Completed | yangtze-river-pharmaceutical-group-co-ltd | Nov 20, 2024 | 224 |
| NCT06109428Pain, Postoperative · United States | 4 | Completed | Heron Therapeutics | Mar 29, 2022 | 37 |
| NCT06109415Pain, Postoperative · United States | 4 | Completed | Heron Therapeutics | Jul 18, 2022 | 30 |
| NCT05950152Pain, Postoperative · China | 2 | Not yet recruiting | Sino Biopharmaceutical | Dec 2023 | 108 |
| NCT05315479Pain, Postoperative · United States | 4 | Terminated | Baudax Bio | Jul 7, 2022 | 19 |
| NCT05125588Pharmacokinetics | 1 | Completed | joint-stock-company-farmak | Feb 26, 2014 | 24 |
| NCT05109312Agnosia · United States | 4 | Active, not recruiting | Heron Therapeutics | Jun 2024 | 90 |
| NCT04911062Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Jul 29, 2022 | 32 |
| NCT03974932Agnosia · United States | 3 | Completed | Heron Therapeutics | Dec 7, 2020 | 116 |
| NCT03955211Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Dec 3, 2021 | 25 |
| NCT03936192Osteoarthritis, Knee | 3 | Withdrawn | Eurofarma Laboratorios | Feb 2021 | 0 |
| NCT03922048Agnosia | 2 | Withdrawn | Heron Therapeutics | Nov 2025 | 0 |
| NCT03907176Agnosia · United States | 3 | Completed | Heron Therapeutics | Oct 25, 2021 | 209 |
| NCT03718039Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Jan 31, 2019 | 78 |
| NCT03695367Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Nov 20, 2018 | 63 |
| NCT03684265Healthy · Russian Federation | 1 | Completed | Boehringer Ingelheim | Oct 30, 2018 | 26 |
| NCT03434275Pain, Postoperative · United States | 3 | Completed | Baudax Bio | May 21, 2019 | 194 |
| NCT03323385Pain, Postoperative · United States | 3 | Completed | Baudax Bio | Sep 26, 2018 | 57 |
| NCT03295721Pain, Postoperative · United States | 3 | Completed | Heron Therapeutics | Jan 8, 2018 | 412 |
| NCT03237481Pain, Postoperative · United States, Belgium | 3 | Completed | Heron Therapeutics | Dec 22, 2017 | 418 |
| NCT03015532Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Apr 20, 2018 | 285 |
| NCT03011333Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Feb 1, 2018 | 243 |
| NCT02720692Pain, Postoperative · United States, Australia, Canada and more | 3 | Completed | Baudax Bio | Mar 2017 | 722 |
| NCT02678286Pain, Postoperative · United States | 3 | Completed | Baudax Bio | Oct 2016 | 219 |
| NCT02675907Pain, Postoperative · United States | 3 | Completed | Baudax Bio | Jul 2016 | 201 |
| NCT02540265Pain, Postoperative · United States | 2 | Completed | Baudax Bio | Nov 2015 | 59 |
| NCT02504580Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Mar 2017 | 463 |
| NCT02471898Agnosia · United States | 2 | Completed | Heron Therapeutics | Sep 2015 | 71 |
| NCT02448199Osteoarthritis | 3 | UNKNOWN | zodiac-produtos-farmaceuticos-s-a | Jun 2016 | 375 |
| NCT02255045Dysmenorrhea · Chile | 3 | Completed | Grünenthal | Feb 21, 2016 | 68 |
| NCT02229747Pharyngitis | 4 | Completed | Boehringer Ingelheim | Feb 2002 | 128 |
| NCT02187575Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2002 | 26 |
| NCT02187562Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2002 | 16 |
| NCT02183181Healthy | 1 | Completed | Boehringer Ingelheim | Jan 2009 | 6 |
| NCT02183168Spondylitis, Ankylosing | 3 | Completed | Boehringer Ingelheim | May 1, 2002 | 192 |
| NCT02183129Osteoarthritis | 4 | Completed | Boehringer Ingelheim | Nov 1, 1999 | 91 |
| NCT02183116Osteoarthritis | 4 | Completed | Boehringer Ingelheim | Feb 1999 | 30 |
| NCT02183077Healthy | 1 | Completed | Boehringer Ingelheim | Nov 1998 | 12 |
| NCT02183064Osteoarthritis | 3 | Completed | Boehringer Ingelheim | Nov 2000 | 1,309 |
| NCT02183051Pain | 2 | Completed | Boehringer Ingelheim | Oct 1998 | 381 |
| NCT02183025Dysmenorrhea | 2 | Completed | Boehringer Ingelheim | Apr 1999 | 337 |
| NCT02181907Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2003 | 22 |
| NCT02181322Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2001 | 24 |
| NCT02181309Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2002 | 24 |
| NCT02180490Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2002 | 60 |
| NCT02180477Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2001 | 9 |
| NCT01839643Contraception · Chile | 1 | Completed | Grünenthal | May 7, 2013 | 13 |
| NCT01750931Arthritis, Rheumatoid | – | Completed | GlaxoSmithKline | Oct 1, 2013 | 28 |
| NCT01587508Acute Lumbago · Brazil | 3 | Withdrawn | Eurofarma Laboratorios | May 2013 | 0 |
| NCT01436032Laparoscopic Surgery · United States | 3 | Terminated | Alkermes | Mar 2012 | 50 |
| NCT01430559Osteoarthritis, Knee · China | – | Completed | Pfizer | Mar 27, 2013 | 408 |
| NCT01161147Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Dec 2004 | 28 |
| NCT01161134Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Nov 2004 | 28 |
| NCT01084161Hysterectomy · Georgia, Poland, Serbia | 2 | Completed | Alkermes | Jan 2011 | 486 |
| NCT00945763Toothache · United States | 2 | Completed | Alkermes | Nov 2009 | 230 |
| NCT00840879Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Feb 2004 | 28 |
| NCT00840476Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Feb 2004 | 28 |
| NCT00649675Healthy · United States | 1 | Completed | Viatris | Sep 2004 | 27 |
| NCT00649077Healthy · United States | 1 | Completed | Viatris | Sep 2004 | 30 |
| NCT00618163Inflammation · United States | – | Completed | Hikma Pharmaceuticals | Apr 2005 | 47 |
How it is read
Names in the registry
- “HTX-011”, 20 entries
- “N1539”, 18 entries
- “Meloxicam”, 12 entries
- “Meloxicam tablet”, 3 entries
- “Meloxicam 15 mg Tablets”, 2 entries
Conditions, from the studies’ own filings
- Pain, Postoperative, 21 studies
- Osteoarthritis, 6 studies
- Arthritis, Rheumatoid, 3 studies
- Hernia, Inguinal, 2 studies
- Pain, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.